Zhejiang East-Asia Pharmaceutical (605177.SH): The raw material drug Lu Likang received the South Korean raw material drug registration certificate.
East Asia Pharmaceutical (605177.SH) issued an announcement that they recently received approval from the South Korean Food and Drug Administration (Korea...
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that recently, the company has received the raw material drug registration certificate from the South Korean Ministry of Food and Drug Safety (Korean MFDS) for the product named Voriconazole. Voriconazole is used to treat skin superficial fungal infections caused by sensitive fungi, such as athlete's foot, body ringworm, jock itch, and can also be used for cutaneous candidiasis and tinea versicolor.
The receipt of the Voriconazole raw material drug registration certificate in South Korea marks the company's eligibility for market access in South Korea. This will have a positive impact on expanding the company's presence in the South Korean pharmaceutical market, thus promoting the sales of Voriconazole raw material drugs in other overseas markets.
Related Articles

Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


